최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Korean journal of clinical laboratory science : KJCLS = 대한임상검사과학회지, v.52 no.1, 2020년, pp.62 - 68
최재선 (극동대학교 임상병리학과)
Cisplatin (CDDP) is a chemotherapy agent used for patients with ovarian cancers. CDDP activates multiple signaling pathways, which causes various cellular reactions according to the type of cancer cells. Therefore, it is difficult to clearly conclude its signaling pathways. The purpose of this study...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
세포 사멸(apoptosis)은 어떤 순서로 이루어지는가? | 이에 따라 부작용을 줄이기 위해 cisplatin과 함께 사용할 수 있는 물질과의 병용요법이나 cisplatin이 가지는 다중 신호경로를 타겟으로 세포 사멸을 유도하는 새로운 치료 전략으로의 연구가 진행되고 있다. 세포 사멸(apoptosis)의 경로는 연속적인 진행 과정으로 초기 세포사멸의 활성화 단계인 핵 내의 신호전달, 전 이단계인 미토콘드리아에서의 단백질 조절 및 실행 그리고 실행 단계인 세포질에서의 단백질 분해 등으로 구조적 변화가 일어나는 순서로 이어진다[6]. 세포 사멸을 일으키는 암세포의 성향은 화학 요법제와 반응하여 결정되는 중요한 요소이고 종종 암세포는 세포 사멸을 조절하는 변이 유전자를 가진다[7, 8]. | |
Cisplatin이란 무엇인가? | Cisplatin (cis-[Pt(NH3)2 Cl2], CDDP)은 난소암 등의 고형 암 치료에 사용되는 가장 강력한 화학 요법제 중 하나이다. Cisplatin을 포함하는 백금 기반의 항암제들은 실제 cisplatin이 임상 실험에서 성공한 후 수많은 연구자들의 수고와 노력에 의하여 발견되고 발전하였다[4, 5]. | |
MAPKs의 3가지 주요그룹은 어떠한 역할을 하는가? | MAPKs의 3가지 주요 그룹은 ERK (extracellular signalregulated protein kinases), JUN (c-JUN N-terminal kinase/stress-activaed protein kinase)과 p38 subfamilies로 포유동물 세포내 발견된다. 각각의 그룹은 다양한 세포 외부의 자극과 스트레스를 통해 세포 내부의 경로가 변화될 수 있도록 조절하는 단백질들을 가진다[12, 13]. Cisplatin은 세포의 종류 및 치료 용량에 따라 세포 반응을 조절하기 위하여 다중 신호 경로를 활성화 시킨다[34]. |
Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009;4:287-313. https://doi.org/10.1146/annurev.pathol.4.110807.092246
Swisher EM, Taniguchi T, Karlan BY. Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. J Natl Cancer Inst. 2012;104:642-645. https://doi.org/10.1093/jnci/djs203
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68:7-30. https://doi.org/10.3322/caac.21442
Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D, et al. Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des. 2010;16:1813-1825. https://doi.org/10.2174/138161210791209009
Chen D, Milacic V, Frezza M, Dou QP. Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des. 2009;15:777-791. https://doi.org/10.2174/138161209787582183
Goldstein P. Controlling cell death. Science. 1997;275:1081-1082. https://doi.org/10.1126/science.275.5303.1081
Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000;19:2324-2330. https://doi.org/10.1038/sj.onc.1203598
Lasky T, Silbergeld E. P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. Environ Health Perspect. 1996;104:1324-1331. https://doi.org/10.1289/ehp. 961041324
Kulik G, Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol. 1998;18:6711-6718. https://doi.org/10.1128/mcb.18.11.6711
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29-39. https://doi.org/10.1016/s0092-8674(00)81780-8
Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin-and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol. 1998;143:1375-1383. https://doi.org/10.1083/jcb.143.5.1375
Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol. 1998;10:205-219. https://doi.org/10.1016/s0955-0674(98)80143-9
Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann N Y Acad Sci. 1998;30:139-146. https://doi.org/10.1111/j.1749-6632.1998.tb08987.x
Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275:39435-39443. https://doi.org/10.1074/jbc.M004583200
Tang MK, Zhou HY, Yam JW, Wong AS. c-Met over expression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia. 2010;12:128-138. https://doi.org/10.1593/neo.91438
Chen G, Gong M, Yan M, Zhang X. Sevoflurane induces endoplasmic reticulum stress mediated apoptosis in hippocampal neurons of aging rats. PLoS ONE. 2013;8:E57870. https://doi.org/10.1371/journal.pone.0057870
Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell. 1997;91:443-446. https://doi.org/10.1016/s0092-8674(00)80430-4
Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798-4811. https://doi.org/10.1038/sj.onc.1209608
Salvesen GS, Abrams JM. Caspase activation-stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene. 2004;23:2774-2784. https://doi.org/10.1038/sj.onc.1207522
Cohen TT. Apoptosis. Immunol. 1993;14:126-130. https://doi.org/10.1016/0167-5699(93)90214-6
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53:3976-3985.
Muscella A, Calabriso N, Fanizzi FP, De Pascali SA, Urso L, Ciccarese A, et al. Pt [(O,O'-acac)(gamma-acac)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway. Br J Pharmacol. 2008;153:34-49. https://doi.org/10.1038/sj.bjp.0707576
Hail N Jr, Lotan R. Cancer chemoprevention and mitochondria: targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state. Mol Nutr Food Res. 2009;53:49-67. https://doi.org/10.1002/mnfr.200700527
Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, et al. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol. 2005;289:C1466-1475. https://doi.org/10.1152/ajpcell.00265.2005
Siddik ZH. Cisplatin: mode of cytoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-7279. https://doi.org/10.1038/sj.onc.1206933
Park SJ, Kim IS. The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol. 2005;146:506-513. https://doi.org/10.1038/sj.bjp.0706360
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537-549. https://doi.org/10.1038/nrc2694
Bulavin DV, Fornace AJ. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95-118. https://doi.org/10.1016/S0065-230X(04)92005-2
Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37-40. https://doi.org/10.1038/35065000
Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911-1912. https://doi.org/10.1126/science.1072682
Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci. 2001;26:657-664. https://doi.org/10.1016/s0968-0004(01)01958-2
Achkar IW, Abdulrahman N, Al-ulaiti H. Joseph JM, Uddin S, Mraiche F. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J Transl Med. 2018;16:96. https://doi.org/10.1186/s12967-018-1471-1
Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J. Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci. 2013;14:9536-9555. https://doi.org/10.3390/ijms14059536
※ AI-Helper는 부적절한 답변을 할 수 있습니다.